Skip to main content

Table 1 Clinical characteristics of simulated cohort

From: Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K

Parameter Value
Age (years)  
   Mean 58
   Range 29–88
Gender (% Female) 38%
Race  
   Caucasian 92%
   Afro-Caribbean 4%
   Asian 4%
Initial resulting HbA1c level (mean)  
   Metformin monotherapy 7.6%
   Combination therapy 6.9%
HbA1c annual upward drift 0.15%